Literature DB >> 30087961

Immunoglobulin light chain amyloid aggregation.

Luis M Blancas-Mejia1, Pinaki Misra, Christopher J Dick, Shawna A Cooper, Keely R Redhage, Michael R Bergman, Torri L Jordan, Khansaa Maar, Marina Ramirez-Alvarado.   

Abstract

Light chain (AL) pan class="Disease">amyloidosis is a devastating, complex, and incurable protein misfolding disease. It is characterized by an abnormal proliferation of plasma cells (fully differentiated B cells) producing an excess of monoclonal immunoglobulin light chains that are secreted into circulation, where the light chains misfold, aggregate as amyloid fibrils in target organs, and cause pan class="Disease">organ dysfunction, organ failure, and death. In this article, we will review the factors that contribute to AL amyloidosis complexity, the findings by our laboratory from the last 16 years and the work from other laboratories on understanding the structural, kinetics, and thermodynamic contributions that drive immunoglobulin light chain-associated amyloidosis. We will discuss the role of cofactors and the mechanism of cellular damage. Last, we will review our recent findings on the high resolution structure of AL amyloid fibrils. AL amyloidosis is the best example of protein sequence diversity in misfolding diseases, as each patient has a unique combination of germline donor sequences and multiple amino acid mutations in the protein that forms the amyloid fibril.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30087961      PMCID: PMC6148388          DOI: 10.1039/c8cc04396e

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  123 in total

1.  The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution.

Authors:  O Epp; E E Lattman; M Schiffer; R Huber; W Palm
Journal:  Biochemistry       Date:  1975-11-04       Impact factor: 3.162

2.  The Antibody Light-Chain Linker Is Important for Domain Stability and Amyloid Formation.

Authors:  Cardine N Nokwe; Manuel Hora; Martin Zacharias; Hisashi Yagi; Christine John; Bernd Reif; Yuji Goto; Johannes Buchner
Journal:  J Mol Biol       Date:  2015-09-25       Impact factor: 5.469

3.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.

Authors:  Richard W McLaughlin; Janelle K De Stigter; Laura A Sikkink; Elizabeth M Baden; Marina Ramirez-Alvarado
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

4.  The N-terminal strand modulates immunoglobulin light chain fibrillogenesis.

Authors:  Luis del Pozo-Yauner; Jonathan S Wall; Martín González Andrade; Rosana Sánchez-López; Sandra L Rodríguez-Ambriz; Julio I Pérez Carreón; Adrián Ochoa-Leyva; D Alejandro Fernández-Velasco
Journal:  Biochem Biophys Res Commun       Date:  2013-12-07       Impact factor: 3.575

5.  Preparation and properties of crystals of a Bence-Jones dimer with mercury inserted into the interchain disulfide bond.

Authors:  K R Ely; R L Girling; M Schiffer; D E Cunningham; A B Edmundson
Journal:  Biochemistry       Date:  1973-10-09       Impact factor: 3.162

6.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Authors:  Shikha Mishra; Jian Guan; Eva Plovie; David C Seldin; Lawreen H Connors; Giampaolo Merlini; Rodney H Falk; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

7.  Tertiary structure of human lambda 6 light chains.

Authors:  P R Pokkuluri; A Solomon; D T Weiss; F J Stevens; M Schiffer
Journal:  Amyloid       Date:  1999-09       Impact factor: 7.141

8.  Cocrystallization of an immunoglobulin light chain dimer with bis(dinitrophenyl) lysine: tandem binding of two ligands, one with and one without accompanying conformational changes in the protein.

Authors:  A B Edmundson; K R Ely; X M He; J N Herron
Journal:  Mol Immunol       Date:  1989-03       Impact factor: 4.407

9.  A molten globule intermediate of the von Willebrand factor A1 domain firmly tethers platelets under shear flow.

Authors:  Alexander Tischer; Pranathi Madde; Luis M Blancas-Mejia; Matthew Auton
Journal:  Proteins       Date:  2013-11-22

10.  Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein.

Authors:  Marcus D Tuttle; Gemma Comellas; Andrew J Nieuwkoop; Dustin J Covell; Deborah A Berthold; Kathryn D Kloepper; Joseph M Courtney; Jae K Kim; Alexander M Barclay; Amy Kendall; William Wan; Gerald Stubbs; Charles D Schwieters; Virginia M Y Lee; Julia M George; Chad M Rienstra
Journal:  Nat Struct Mol Biol       Date:  2016-03-28       Impact factor: 15.369

View more
  15 in total

1.  Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.

Authors:  Roberta Fenoglio; Simone Baldovino; Michela Ferro; Savino Sciascia; Gianluca Rabajoli; Giacomo Quattrocchio; Giulietta Beltrame; Carla Naretto; Daniela Rossi; Mirella Alpa; Antonella Barreca; Mario Giulio Papotti; Dario Roccatello
Journal:  J Nephrol       Date:  2020-05-29       Impact factor: 3.902

2.  Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion.

Authors:  Bibiana Rius; Jaleh S Mesgarzadeh; Isabelle C Romine; Ryan J Paxman; Jeffery W Kelly; R Luke Wiseman
Journal:  Blood Adv       Date:  2021-02-23

3.  A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.

Authors:  Daniele Peterle; Elena S Klimtchuk; Thomas E Wales; Florian Georgescauld; Lawreen H Connors; John R Engen; Olga Gursky
Journal:  J Mol Biol       Date:  2021-10-19       Impact factor: 5.469

Review 4.  Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis.

Authors:  Emily Lewkowicz; Olga Gursky
Journal:  Biophys Chem       Date:  2021-10-14       Impact factor: 3.628

5.  Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.

Authors:  Paolo Swuec; Francesca Lavatelli; Masayoshi Tasaki; Cristina Paissoni; Paola Rognoni; Martina Maritan; Francesca Brambilla; Paolo Milani; Pierluigi Mauri; Carlo Camilloni; Giovanni Palladini; Giampaolo Merlini; Stefano Ricagno; Martino Bolognesi
Journal:  Nat Commun       Date:  2019-03-20       Impact factor: 14.919

6.  Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.

Authors:  Lynn Radamaker; Yin-Hsi Lin; Karthikeyan Annamalai; Stefanie Huhn; Ute Hegenbart; Stefan O Schönland; Günter Fritz; Matthias Schmidt; Marcus Fändrich
Journal:  Nat Commun       Date:  2019-03-20       Impact factor: 14.919

7.  Different Dynamics in 6aJL2 Proteins Associated with AL Amyloidosis, a Conformational Disease.

Authors:  Roberto Maya-Martinez; Leidys French-Pacheco; Gilberto Valdés-García; Nina Pastor; Carlos Amero
Journal:  Int J Mol Sci       Date:  2019-08-21       Impact factor: 5.923

Review 8.  Protein Misfolding during Pregnancy: New Approaches to Preeclampsia Diagnostics.

Authors:  Elizaveta M Gerasimova; Sergey A Fedotov; Daniel V Kachkin; Elena S Vashukova; Andrey S Glotov; Yury O Chernoff; Aleksandr A Rubel
Journal:  Int J Mol Sci       Date:  2019-12-07       Impact factor: 5.923

Review 9.  CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.

Authors:  Dario Roccatello; Roberta Fenoglio; Savino Sciascia; Carla Naretto; Daniela Rossi; Michela Ferro; Antonella Barreca; Fabio Malavasi; Simone Baldovino
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

10.  Alpha-B-Crystallin Effect on Mature Amyloid Fibrils: Different Degradation Mechanisms and Changes in Cytotoxicity.

Authors:  Olga V Stepanenko; M I Sulatsky; E V Mikhailova; Olesya V Stepanenko; O I Povarova; I M Kuznetsova; K K Turoverov; A I Sulatskaya
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.